Conduit to Change Name to CDT Equity Inc.

Core Perspective - The company is rebranding from Conduit Pharmaceuticals Inc. to CDT Equity Inc. to reflect its evolved strategy as a data-driven biotech firm focused on enhancing high-potential therapeutic assets through scientific innovation and strategic partnerships [1] Group 1: Company Strategy - CDT's strategy focuses on unlocking the value of clinical-stage compounds that larger pharmaceutical companies have deprioritized, despite having strong Phase I safety data [2] - The company utilizes advanced co-crystallization and solid-form technologies to improve drug properties and has successfully extended the patent life of certain drugs by up to 20 years [2] - The current pipeline includes candidates targeting inflammatory and autoimmune disorders, idiopathic male infertility, dermatology, and animal health [2] Group 2: Collaborations and Innovations - A collaboration with Sarborg allows CDT to use AI-powered disease mapping to identify novel repurposing opportunities, leading to two new combination patent filings that strengthen its intellectual property portfolio [3] - CDT has initiated pre-clinical in-vitro models to explore new indications guided by AI insights, aiming to progress out-licensing opportunities based on successful trials [3] - A partnership with Manoira enables CDT to expand into the animal health market while retaining 100% ownership of all data and intellectual property related to human applications, potentially enhancing its human therapeutic pipeline and creating new revenue streams [4] Group 3: Operational Model and Future Outlook - CDT operates with a lean, disease-agnostic model that prioritizes speed, adaptability, and capital efficiency, avoiding the costs associated with late-stage clinical trials [6] - The company is committed to creating shareholder value through licensing, strategic mergers and acquisitions, and positioning itself as a platform for transformative innovation [6] - CDT is evaluating a cryptocurrency treasury reserve strategy to explore potential strategic and financial benefits as part of a diversified capital management approach [5]